Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sildenafil + losartan
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of sildenafil, a phosphodiesterase-5 (PDE5) inhibitor used for erectile dysfunction, and losartan, an angiotensin II receptor blocker (ARB) used for hypertension. This combination may have additive effects on lowering blood pressure and potentially beneficial effects on erectile function, particularly in diabetic patients.
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on sildenafil + losartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sildenafil + losartan.